Clinical Trial Search

Primary: Percentage of Participants With an Objective Response Rate (ORR) According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 0; 0; 37.5; 62.5 Percentage of…

Primary: Clinical Global Impression - Improvement (CGI-I) Score — 12; 8; 0; 0 Participants

Primary: Overall Response Rate [Complete Response + Very Good Partial Response + Partial Response (CR + VGPR + PR)] — 42 Participants

Primary: Progession Free Survival — 85.7 % of participants without progression

Primary: Tumor Response According to RECIST Criteria — 0; 0; 0; 5 Participants

Primary: Percentage of Participants That Are Able to Meet Feasibility Parameters. — 100 percentage of participants

Primary: Local Control Assessment of Unresectable Paranasal Sinus and Nasal Cavity Tumors

Primary: Change in Brief Smell Identification Test (BSIT) — 6.77; 7.20; 7.89; 7.88 score on a scale

Primary: Alpha-synuclein Levels From Nasal Swabs

Primary: The Number of Patients With a Score of 21 or Greater by the Visual Assessment Weighted Score (VAWS). — 34 Participants

Primary: Overall Response Rate (ORR) — 7; 5 percentage of participants

Primary: Maximum Tolerated Dose — 18.6 mCi/kg

Primary: Objective Tumor Response After One Course of Therapy — 5; 5; 11 Participants

Primary: Volumetric Response Rate — 0; 9 Participants

Primary: Change From Visit 1 at End of Study in Bilateral Nasal Polyp Grade Using Endoscopic Video — -0.7 units on a scale

Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants

Primary: Proportion of Patients With Hearing Response — 0.36; 0.50 Proportion with hearing response

Primary: Change in Mean Survey Response From Baseline to 90 Days Post Surgery — 17.3; 13.5 units on a scale — p=0.001

Primary: Comparison of the Number of Lesions Detected as Positive by [123I]mIBG Planar Scintigraphy Which Are Also Considered Positive With [124I]mIBG PET/CT. — 714; 405 Lesions…

Primary: Change From Baseline in Symptoms as Measured by a Composite Score for Each Symptom of Nasal Congestion, Facial Pain or Pressure Sensation, and Nasal Discharge (Anterior…

Primary: Efficacy at Completion of Treatment

Primary: Percentage of MIBG Avid Patients Treated With Meta-iodobenxylguanide (MIBG) Labeled With Iodine-131 — 86.8 Percentage of participants

Primary: Percentage of Dose-limiting Toxicities — 0; 0; 17 Percentage of dose-limiting toxicities

Primary: 1-year Local Control — NA; NA months

Primary: Progression Free Survival, Assessed by Revised Assessment in Neuro-oncology (RANO) Criteria — 11 participants

Primary: The Number of Patients With Severe Adverse Events and Adverse Reactions — 0 Participants

Primary: Response (Complete Response, Very Good Partial Response, and Partial Response) at 60-days Post Stem Cell Infusion — 4; 3 participants

Primary: Number of Participants With Immediate and Short Term Toxicity of Infusion Over 8 Weeks — 0; 0; 3 Participants

Primary: Overall Response - Complete Response (CR), Very Good Partial Response (VGPR) and Partial Response (PR) — 5; 3 participants

Primary: Number of Patients With Unacceptable Dose Limiting Toxicities (DLTs) — 1; 2; 9; 18 participants